Research programme: melanocortin receptor 4 targeting therapeutics - Congruence Therapeutics
Alternative Names: CGX program 1 - Congruence Therapeutics; CGX program 1/2 - Congruence TherapeuticsLatest Information Update: 30 Jun 2023
At a glance
- Originator Congruence Therapeutics
- Class Obesity therapies; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Obesity
Most Recent Events
- 02 Jun 2023 Early research in Obesity in Canada (unspecified route) (Congruence Therapeutics pipeline, June 2023)